Lane Nancy E, Yao Wei, Balooch Mehdi, Nalla Ravi K, Balooch Guive, Habelitz Stefan, Kinney John H, Bonewald Lynda F
Department of Medicine, University of California at Davis, Sacramento, California 95817, USA.
J Bone Miner Res. 2006 Mar;21(3):466-76. doi: 10.1359/JBMR.051103. Epub 2005 Nov 14.
This study compares changes in bone microstructure in 6-month-old male GC-treated and female ovariectomized mice to their respective controls. In addition to a reduction in trabecular bone volume, GC treatment reduced bone mineral and elastic modulus of bone adjacent to osteocytes that was not observed in control mice nor estrogen-deficient mice. These microstructural changes in combination with the macrostructural changes could amplify the bone fragility in this metabolic bone disease.
Patients with glucocorticoid (GC)-induced secondary osteoporosis tend to fracture at higher bone mineral densities than patients with postmenopausal osteoporosis. This suggests that GCs may alter bone material properties in addition to BMD and bone macrostructure.
Changes in trabecular bone structure, elastic modulus, and mineral to matrix ratio of the fifth lumbar vertebrae was assessed in prednisolone-treated mice and placebo-treated controls for comparison with estrogen-deficient mice and sham-operated controls. Compression testing of the third lumbar vertebrae was performed to assess whole bone strength.
Significant reductions in trabecular bone volume and whole bone strength occurred in both prednisolone-treated and estrogen-deficient mice compared with controls after 21 days (p < 0.05). The average elastic modulus over the entire surface of each trabecula was similar in all the experimental groups. However, localized changes within the trabeculae in areas surrounding the osteocyte lacunae were observed only in the prednisolone-treated mice. The size of the osteocyte lacunae was increased, reduced elastic modulus around the lacunae was observed, and a "halo" of hypomineralized bone surrounding the lacunae was observed. This was associated with reduced (nearly 40%) mineral to matrix ratio determined by Raman microspectroscopy. These localized changes in elastic modulus and bone mineral to matrix ratio were not observed in the other three experimental groups.
Based on these results, it seems that GCs may have direct effects on osteocytes, resulting in a modification of their microenvironment. These changes, including an enlargement of their lacunar space and the generation of a surrounding sphere of hypomineralized bone, seem to produce highly localized changes in bone material properties that may influence fracture risk.
本研究比较了6个月大的经糖皮质激素(GC)处理的雄性小鼠和去卵巢雌性小鼠与其各自对照相比骨微结构的变化。除了小梁骨体积减少外,GC处理还降低了骨细胞附近骨的骨矿物质和弹性模量,而在对照小鼠和雌激素缺乏小鼠中未观察到这种情况。这些微观结构变化与宏观结构变化相结合,可能会加剧这种代谢性骨病中的骨脆性。
糖皮质激素(GC)诱导的继发性骨质疏松患者比绝经后骨质疏松患者在更高的骨矿物质密度下更容易骨折。这表明GC除了影响骨密度和骨宏观结构外,还可能改变骨材料特性。
评估泼尼松龙处理的小鼠和安慰剂处理的对照小鼠第五腰椎小梁骨结构、弹性模量以及矿物质与基质比例的变化,并与雌激素缺乏小鼠和假手术对照进行比较。对第三腰椎进行压缩测试以评估全骨强度。
与对照组相比,泼尼松龙处理的小鼠和雌激素缺乏的小鼠在21天后小梁骨体积和全骨强度均显著降低(p < 0.05)。所有实验组中每个小梁整个表面的平均弹性模量相似。然而,仅在泼尼松龙处理的小鼠中观察到骨细胞陷窝周围小梁内的局部变化。骨细胞陷窝大小增加,陷窝周围弹性模量降低,并且在陷窝周围观察到低矿化骨的“晕圈”。这与拉曼光谱法测定的矿物质与基质比例降低(近40%)相关。在其他三个实验组中未观察到弹性模量和骨矿物质与基质比例的这些局部变化。
基于这些结果,似乎GC可能对骨细胞有直接作用,导致其微环境发生改变。这些变化,包括陷窝空间扩大和周围低矿化骨球的形成,似乎会在骨材料特性中产生高度局部化的变化,可能影响骨折风险。